Accessibility Menu
Sol-Gel Technologies logo

Sol-Gel Technologies(NASDAQ) SLGL

Market Cap$287.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-35%
5 Year-12%
1 Year+502%
1 Month+18%
$86.34
-0.64%
-0.56Today
After hours$88.50+$2.16 (+2.50%)
Sol-Gel Technologies last closing stock price
MetricPriceDate
Last closeUSD 88.002026-08-07
Sol-Gel Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.99%USD 82.252026-07-31
1 month+17.71%USD 74.762026-07-08
3 month+24.19%USD 70.862026-05-08
Year to date+108.83%USD 42.142025-12-31
1 year+502.33%USD 14.612025-08-07
3 year+165.86%USD 33.102023-08-08
5 year-12.26%USD 100.302021-08-06
Since inception-35.48%USD 136.402018-02-01

Sol-Gel Technologies Financials at a Glance

Market Cap

$287.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$18.47M

Net Income (TTM)

-$1.05M

EPS (TTM)

-$0.35

P/E Ratio

-250.50

Dividend

$0.00

Beta (Volatility)

0.48 (Low)

Price

$86.34

Volume

46,381.366

Open

$88.78

Previous Close

$88.00

Daily Range

$81.37 - $88.78

52-Week Range

$14.78 - $97.97

Estimated Earnings Date

Aug 21, 2026

SLGL News

302 is a buy

Is Sol-Gel Technologies a Buy?

Maxx ChatskoFeb 3, 2020
dude tossing stacks

Here's Why Sol-Gel Technologies Stock Is Soaring Today

Maxx ChatskoDec 31, 2019

SLGL: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a pharmaceutical company focused on developing and commercializing innovative skin-applied medications. Utilizing unique microencapsulation technology, the company aims to address various dermatological conditions through its advanced product pipeline.

Products and Services
  • Twyneo: A non-antibiotic topical cream for acne vulgaris
  • Epsolay: A once-daily cream for treating papulopustular rosacea
  • SGT-210: A candidate for palmoplantar keratoderma currently in Phase I trials
Growth Outlook
  • Successful Phase III trials for Twyneo and Epsolay enhance market potential
  • Strategic partnership with Perrigo supports product development and distribution
  • Ongoing research into treatments for psoriasis and other conditions expands pipeline
Financial Highlights
  • Recent quarterly revenue of $108,000 shows potential for growth
  • Cash and short-term investments total $52.8 million, providing operational flexibility
  • Current ratio of 8.84 indicates strong liquidity position
Sol-Gel Technologies Ltd. is positioned in the biotechnology sector, focusing on dermatological treatments. The company has made significant strides in clinical development, particularly with its lead products, Twyneo and Epsolay, which have completed Phase III trials. These advancements not only validate the company's innovative approach but also enhance its potential for market entry. The strategic partnership with Perrigo is noteworthy, as it may facilitate broader distribution and commercialization of Sol-Gel's products. The ongoing research into additional treatments for conditions like psoriasis further diversifies the company's portfolio, potentially leading to increased revenue streams. Financially, Sol-Gel has demonstrated a solid liquidity position with substantial cash reserves, allowing for continued investment in research and development. The recent quarterly revenue, while modest, reflects the company's early-stage growth potential. Overall, Sol-Gel Technologies Ltd. presents an intriguing opportunity for investors interested in the biotechnology space, particularly in innovative dermatological solutions.
AI Generated • Jul 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

28

CEO

Moshe Arkin

Website

www.sol-gel.com

Headquarters

Ness Ziona, TA 7403650, IL

SLGL Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-12.59%

Net Income Margin

-5.66%

Return on Equity

-3.17%

Return on Capital

-31.67%

Return on Assets

-1.79%

Earnings Yield

-0.40%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$287.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.27M

Volume

46.38K

Avg. Volume

39.15K

Financials (TTM)

Gross Profit

$18.47M

Operating Income

-$2.32M

EBITDA

-$1.98M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$52.83M

Total Debt

$862.00K

Sol-Gel Technologies Performance Analysis

Sol-Gel Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,883,000-87.6%
20232023-12-31USD 1,554,000-60.0%
20242024-12-31USD 11,538,000642.5%
20252025-12-31USD 19,388,00068.0%
Sol-Gel Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301574.2%
Q32025-09-30-97.7%
Q42025-12-3174.0%
Q12026-03-31-84.5%
Sol-Gel Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -6.45N/A
20232023-12-31USD -10.0655.8%
20242024-12-31USD -3.80-62.2%
20252025-12-31USD -2.20-42.1%
Sol-Gel Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301403.1%
Q32025-09-30-151.1%
Q42025-12-3149.8%
Q12026-03-31-22.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$108.00K

-89.5%

Gross Profit

$108.00K

-89.5%

Gross Margin

100.00%

N/A

Market Cap

$287.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.27M

N/A

Employees

28

N/A

Net Income

-$3.73M

+57.7%

EBITDA

-$3.86M

+57.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$52.83M

+212.6%

Total Debt

$862.00K

-26.9%

Accounts Receivable

$1.07M

-72.5%

Inventory

$0.00

N/A

Long Term Debt

$377.00K

-49.5%

Short Term Debt

$485.00K

+12.0%

Return on Assets

-1.79%

N/A

Return on Invested Capital

-4.45%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZNTLZentalis Pharmaceuticals, Inc.
$4.22-15.60%
MGNXMacroGenics, Inc.
$4.04+0.75%
ORMPOramed Pharmaceuticals Inc.
$4.30+0.00%
COYACoya Therapeutics, Inc.
$4.81+5.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About SLGL

What is the current price of Sol-Gel Technologies?

Sol-Gel Technologies is trading at $88.00 per share.

What is the 52-week range for Sol-Gel Technologies?

Over the past 52 weeks, Sol-Gel Technologies has traded between $14.78 and $97.97.

How much debt does Sol-Gel Technologies have?

As of the most recent reporting period, Sol-Gel Technologies reported total debt of $862.00K.

How much cash does Sol-Gel Technologies have on hand?

Sol-Gel Technologies reported $10.14M in cash and cash equivalents in its most recent financial results.

What is Sol-Gel Technologies’s dividend yield?

Sol-Gel Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services